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 African Trypanosomiasis, also known as sleeping sickness, caused by the 
protozoan Trypanosoma brucei, is a neglected tropical disease. This disease can be 
successfully controlled, as has been proven in the past; nevertheless, the growing 
number of people affected and at risk makes the development of a vaccine a priority. T. 
brucei is capable of constantly evading the host immune system, due to a remarkable 
mechanism of defense, which provides a great antigenic variation. Due to this 
mechanism it has been very difficult to develop an effective vaccine. However, new 
approaches have been pursued, one of which, the vaccination strategy with plasmid 
DNA has revealed some promising results. Based on this, this work aims to use three 
immunization strategies: the first one, DNA vaccination, using two plasmids DNA, 
encoding antigenic candidates from Trypanosoma brucei; the second one, using these 
antigenic candidates together with a nanoformulation; and the third one, using VLPs 
(Virus-Like Particles). The three models used in the development of DNA vaccines 
against T. brucei use two important proteins of the parasite: MSP (Major Surface 
Protease) and PLC (Phospholipase C).  MSP is a surface zinc metalloprotease that is 
believed to be responsible by the release of a VSG (Variable Surface Glycoprotein) 
fragment. PLC is a phospholipase anchored to a GPI (Glycosylphosphatidylinositol) 
residue that cleaves a full-length VSG protein from the cell surface. As we can see, both 
proteins are responsible by the VSG release, by the normal differentiation from 
bloodstream to procyclic form, and they participate synergistically in VSG loss during 
differentiation. 
 After immunization with the first two strategies, although the titres were low, 
mice produced antibodies anti-Trypanosoma brucei brucei. The animals that presented 
a better immune response were the ones immunized with the mix of plasmids together 
with the nanoformulation. Regarding the third model of immunization, the design of the 
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 A tripanosomose Africana, também conhecida como Doença do Sono, causada 
pelo protozoário Trypanosoma brucei, é uma doença tropical negligenciada. Esta 
doença pode ser controlada, tal como foi provado no passado; no entanto, o crescente 
número de pessoas afectadas e em risco torna o desenvolvimento de uma vacina uma 
prioridade. T. brucei é capaz de evadir constantemente o sistema imunitário do 
hospedeiro, devido ao seu extraordinário mecanismo de defesa, que lhe proporciona 
uma grande variação antigénica. Devido a este mecanismo de defesa tem sido muito 
difícil de desenvolver uma vacina eficaz. Contudo, têm sido procuradas novas técnicas, 
entre elas, uma estratégia de vacinação com DNA plasmídico que têm revelado 
resultados promissores. Tendo em conta estes resultados, este trabalho tem como 
objectivo o uso de três estratégias de imunização: a primeira, recorrendo a vacinas de 
DNA, usando dois plasmídeos que codificam candidatos antigénicos de Trypanosoma 
brucei; a segunda, usando estes candidatos antigénicos conjugados com uma nano-
formulação; e a terceira, usando VLPs (Vírus-Like Particles). Os três modelos usados 
no desenvolvimento de vacinas de DNA contra T. brucei recorreram ao uso de duas 
importantes proteínas do parasita: a MSP (Major Surface Protease) e a PLC 
(Phospholipase C). A MSP é uma metaloprotease de zinco de superfície, que se acredita 
ser responsável pela libertação de um fragmento de VSG (Variable Surface 
Glycoprotein). A PLC é uma fosfolipase, ancorada a um resíduo de GPI 
(Glycosylphosphatidylinositol), que cliva integralmente uma proteína de VSG da 
superfície da célula. Como se pode ver, ambas as proteínas são responsáveis pela 
libertação das VSG, pela normal diferenciação da forma procíclica para a forma de 
corrente, e participam de forma sinérgica para a perda de VSG durante a diferenciação. 
 Após a imunização com as duas primeiras estratégias, apesar de em baixos 
níveis, os murganhos produziram anticorpos anti-Trypanosoma brucei brucei. Os que 
apresentaram melhor resposta imunológica foram os imunizados com a mistura de 
plasmídeos conjugados com a nano-formulação. Em relação ao terceiro modelo de 
imunização, o desenho das VLPs foi efectuado, e o próximo passo é a avaliação 
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1. Introduction 
 
Human African Trypanosomiasis (HAT), also known as, sleeping sickness, is 
caused by the protozoan parasite Trypanosoma brucei, and it is transmitted by the bite 
of tsetse flies (Glossina spp.). There are two subspecies of T. brucei that are pathogenic 
for humans and cause very distinct pathologies: T. b. gambiense and T. b. rhodesiense 
(WHO 2015a). It is estimated that 69.3 million people, in 36 sub-Saharan Africa 
countries, are at risk of having sleeping sickness, 57 million of which are at risk of 
getting T. b. gambiense and 12.3 million T. b. rhodesiense (Simarro et al. 2012; WHO 
2015a). The first descriptions of this disease date back to the colonial period and were 
made by ship doctors and medical officers (WHO 2015b).  
 T. b. gambiense is found in Western and Central Africa (Figure 1A), and causes 
a chronic form of HAT that can have a duration of about 3 years (Checchi et al. 2008). 
On the other hand, T. b. rhodesiense, can be found in Eastern and Southern Africa 
(Figure 1B), causes an acute and fulminant form of the disease, which can lead to death 
within weeks or months (Odiit et al. 1997). 
There is a third subspecies of Trypanosoma brucei parasites: Trypanosoma 
brucei brucei, which causes African Animal Trypanosomiasis and does not infect 
humans, just wild and domestic animals, such as donkeys, horses, goats, camels, mules, 
sheep, antelope. This disease is chronic and sometimes fatal in cattle, however is rarely 
fatal in swine. In animals, the first symptoms are lymphadenopathy, intermittent fever, 
anemia and progressive emaciation. The animal disease can vary between acute or 
chronic depending on the species, the age of the host and the parasite load (Acha & 
Szyfres 2003). This subspecies is widely used in experimental models of animal and 
human African Trypanosomiasis (de Sousa et al. 2010; Lança et al. 2011). 
HAT was close to elimination during the 1960s, due to the establishment of 
systematic screening, treatment, and follow-up of patients for the T. b. gambiense HAT, 
and control of reservoir animals and vectors, in Eastern and Southern Africa, for the T. 
b. rhodesiense HAT (Simarro et al. 2011). The rarity of cases resulted in a lack of 
interest in disease surveillance and a decrease in disease control, which led to the re-
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emergence in the 1980s. This re-emergence reached epidemic proportions, most of the 













Figure 1: Distribution of Human African Trypanosomiasis: A- Distribution of Human African 
Trypanosomiasis (T. b. gambiense) (WHO 2015c); B- Distribution of Human African Trypanosomiasis 
(T. b. rhodesiense) (WHO 2015d). 
 
Due to more health care facilities doing screening and the improvement of the 
diagnostic tests, in 2009, the number of new cases of HAT fell below 10.000 and the 
number of people screened increased (Simarro et al. 2011). 
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1.1 Pathology, diagnosis and treatment of Human African Trypanosomiasis 
 
HAT has two different stages, being the clinical signs slightly different between 
T. b. rhodesiense and T. b. gambiense. However, they have one feature in common, if 
left untreated they can lead to coma and death. 
After inoculation, the trypanosome multiplies at the site of infection, producing 
a local skin reaction, called chancre. This reaction is more common in T. b. rhodesiense 
than in T. b. gambiense, and is the first symptom of this disease (reviewed in Barrett et 
al. 2003). 
The first stage of the disease starts when the parasites reach the draining lymph 
nodes and the bloodstream; this stage goes by the name of haemolymphatic stage. The 
commonest characteristic symptom of this stage is the irregular fever, which reflects the 
parasitemia levels in the blood. Other symptoms, like headache, pruritus and 
lymphadenopathy are also seen. However, there are some differences between East and 
West African trypanosomiasis. In the first one, the symptoms, even at the first stage of 
the disease, can be severe, if there is no quick access to treatment, patients can die. On 
the other hand, in the infection caused by T. b. gambiense the most common signs of the 
disease are lymphoadenopathy (Winterbottom’s sign), hepatosplenomegaly and faint 
rash (reviewed in Stich et al. 2002; Barrett et al. 2003; Brun et al. 2010). 
As the disease progress to the second stage, also known as, meningoencephalitic 
stage, the parasites cross the blood-brain barrier (BBB), invading the central nervous 
system, causing progressive neurological damage. In T. b. rhodesiense, this happens 
within a few weeks of infection, unlike T. b. gambiense, which takes between several 
months to years. The main symptom of the second stage is the sleep disorder; this is 
characterized by deregulation of the circadian rhythm of the sleep cycle and 
fragmentation of the sleeping pattern. Other neurological symptoms are tremor, 
fasciculation, general motor weakness, paralysis of a limb, hemiparesis, akinesia, and 
abnormal movements such as dyskinesia or chorea-athetosis. Difficulty in 
concentration, reduced higher mental functions, are other symptoms which culminate in 
a final state of sleepiness (reviewed in Stich et al. 2002; Barrett et al. 2003; Brun et al. 
2010). 
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This disease needs an accurate and early diagnosis. Control programmes use a 
three-step approach: screening, diagnostic confirmation and staging. The diagnostic 
method may vary between the two forms of the disease. 
The card agglutination test for trypanosomiasis - T. b. gambiense, used in the 
screening step, is a specific and, most of all, fast and practical serological test, that 
allows hundreds of people to be tested daily. Nevertheless, this method has limitations: 
high frequency of equivocal results and a limited sensitivity. Other serological tests 
used to screen, are immunofluorescence and enzyme-like immunosorbent assays 
(ELISA) (Noireau et al. 1988; Lejon et al. 1998). However, in addition to all necessary 
equipment, these techniques are time-consuming, making them mainly used in non-
endemic countries, where the number of samples are lower and the equipment already 
exists. Even though the serologic test comes back negative, in patients who have had 
recent infection or a clinical suspicion of sleeping sickness, health professionals, are 
advised to search for parasites in the blood. For T. b. rhodesiense, there is no serological 
screening test. In this case, screening step has to be done, based on non-specific clinical 
presentation and history of exposure (reviewed in Brun et al. 2010). 
For diagnostic confirmation, a microscopic examination of lymph node aspirate 
and blood, or both, is needed. It might be needed a concentration step, to increase the 
sensitivity of this method (Lutumba et al. 2007). PCR (Polymerase Chain Reaction) on 
blood has 99% sensitivity and 97.7% specificity, but, usually, is impracticable in 
endemic regions, because of the advanced facilities required to perform this method 
(Mugasa et al. 2012). 
In the diagnosis process it is essential to differentiate the stage of the disease, by 
examination of the cerebrospinal fluid (CSF) after lumbar puncture, due to the 
pharmacological differences between the two stages. According to the WHO, the 
presence of trypanosomes in the CSF or a white blood cell count of more than 5 cells 
per µL, or both, defines the late-stage disease (Noireau et al. 1991). The measurement 
of IgM concentrations, in the CSF, is a useful adjunct to the second-stage diagnosis 
(Lejon et al. 2002). 
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There are some non-invasive staging methods, like, polysomnography and 
actigraphy; however, they are not used as a basis for guiding the initial treatment. 
Polysomnography identifies alterations of sleep structure that occur in the late-stage 
HAT (Buguet et al. 2005). Actigraphy uses an actigraph on the wrist to measure body 
movement, and can detect the sleep/wake cycle abnormalities (Njamnshi et al. 2012). 
The treatment of sleeping sickness is based on the disease stage and on the 
subspecies of trypanosome. There are few drugs available to treat this condition.  
First-stage T. b. gambiense HAT is treated with intramuscular pentamidine. This 
drug, although effective has many possible complications, as hyperglycaemia or 
hypoglycaemia, prolongation of the QT interval on electrocardiogram, hypotension and 
gastrointestinal features. The treatment for early-stage T. b. rhodesiense HAT is 
suramin, usually administered intravenously, which has as potential complications renal 
failure, skin lesions, anaphylactic shock, bone marrow toxicity and neurological 
complications (reviewed in Babokhov et al. 2013). 
There is only one drug effective in treating second-stage Eastern HAT, 
melarsoprol. Nevertheless, this drug is very toxic, injections are exceedingly painful, 
and there are records of treatment failures due to resistance. Melarsoprol treatment can 
result in reactive encephalopathy, agranulocytosis, skin rashes, peripheral neuropathy 
and cardiac arrhythmias. Eflornithine is the drug used to treat late-stage T. b. 
gambiense. This drug can cause bone marrow toxicity, alopecia, seizures and 
gastrointestinal symptoms, and there is a potential for drug resistance in the affected 
areas in Africa (reviewed in Kennedy 2013). 
Two new drugs for second-stage gambiense HAT, Fexinidazole and SCYX-
7158, are being evaluated in clinical trials (Jacobs et al. 2011; Tarral et al. 2014). There 
is a study being conducted using melarsoprol, where it was changed the delivery 
method by constructing melarsoprol-cyclodextrin inclusion complexes, and it is a 
promising candidate to treat HAT (Rodgers et al. 2011). 
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1.2 Trypanosoma brucei 
 
1.2.1 Life cycle of Trypanosoma brucei 
 
 Trypanosoma brucei is a heteroxenic protozoan parasite from the 
Trypanosomatidae family and the Kinetoplastida order (reviewed in Simpson et al. 
2006). There are four main developmental stages in the entire life cycle of T. brucei: 
epimastigotes, procyclic forms, slender metacyclic trypomastigotes, and stumpy 
metacyclic trypomastigotes (Figure 2). 
Once an infected tsetse fly takes a blood meal it injects stumpy metacyclic 
trypomastigotes into the mammalian host. The metacyclic trypomastigotes differ into 
proliferative, slender, trypomastigotes that can multiply themselves by binary fission 
throughout the body fluids, such as lymph and cerebrospinal fluid. During the whole 
life cycle in the mammalian host, T. brucei is in the extracellular space. When a tsetse 
fly bites an infected mammal, ingests bloodstream trypomastigotes that differentiate 
into proliferative procyclic trypomastigotes in the tsetse midgut and transform into 
epimastigotes. Then, in the salivary glands, they multiply and transform into non-
proliferative, stumpy, metacyclic trypomastigotes. Only then, the trypanosomes are 










  1. Introduction 
 
  8 
Figure 2: Schematic illustration of the life cycle of Trypanosoma brucei (CDC 2015). 
 
As the parasitemia increases, in the vertebrate host, so does the density (Figure 
3), which induces the parasites to produce a trypanosome factor, the stumpy induction 
factor (SIF). SIF stimulates the transition from slender forms to stumpy forms. These 
forms differ in terms of capacity to proliferate – slender forms proliferate, while stumpy 
forms are arrested; nevertheless, both express the bloodstream stage-specific antigen, 
variant surface glycoprotein (VSG). The fact that stumpy forms are cell-cycle arrested 
combined with an elaborated mitochondrial activity, makes them pre-adapted to life in 
the tsetse vector (Vassella et al. 1997; Tyler et al. 1997). The establishment of parasite 
numbers in the blood and the immune evasion, through antigen variation, is due to the 
proliferation of slender forms. On the contrary, stumpy forms control the expansion of 
parasite numbers in the mammalian host bloodstream and consequently prolonging the 
host survival, increasing the probability of disease transmission (Tyler et al. 2001; 
Mony et al. 2014). 
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Figure 3: Life cycle stages in Trypanosoma brucei (Matthews et al. 2004). 
 
African trypanosomes have at least three different survival strategies that are 
responsible for the persistent infection. The first one, is the antigenic variation of the 
surface coat (Cross 1996); second one, it is observed a repression of stimulatory 
components that results in immunosuppression by unknown mechanisms (reviewed in 
Donelson et al. 1998); and at least, clearance of surface-bound antibodies by the 
parasite motility. However, this clearance is, only effective when the antibody 
concentrations are low, it is not sufficient to protect the cells at high antibody titers 
(Engstler et al. 2007). It is believed, that the antigenic variation and the 
immunosuppression are the reason for the long-term persistence of an infecting 
population, and that the clearance of surface-bound immunoglobulin may contribute for 
the survival of individual cells during the emergence of a specific humoral immune 
response. 
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1.2.2 Cell structure of Trypanosoma brucei parasites 
 
The elongated trypanosome cell (Figure 4) is composed of a highly polarized 
microtubule cytoskeleton, which gives the cell the characteristic shape and maintains it 
intact throughout the cell cycle (Sherwin & Gull 1989). The flagellar pocket is 
positioned at the posterior end of the cell. This structure is the exit point for the 
flagellum and is responsible by all the processes of endo and exocytosis of the parasite 
(reviewed by Overath & Engstler 2004). The motility of the T. brucei depends of its 
single flagellum, a semi-rigid structure found in the Kinetoplastids (Bastin et al. 1998; 
Vaughan & Gull 2003). Nowadays, the flagellum is recognized as the main contributor 
to the pathogenicity of these protozoa. In addition to the motility, it contributes to the 
recognition of the host/vector environment and promotes the recognition and attachment 
necessary for immobilizing the parasite at the vector surfaces at some life-cycle stages 
(Vaughan & Gull 2003). The flagellum begins in the basal body, which in turn, is 
connected through the mitochondrial membrane to the mitochondrial genome which is 
contained by the kinetoplast. A tripartite attachment complex links the basal body and 
the kinetoplast, and has to cross the cell and the mitochondrial membranes (Ogbadoyi et 
al. 2003). 
 
Figure 4: Schematic drawing of the T. brucei structure (Vaughan & Gull 2003). 
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1.2.3 The Variant Surface Glycoprotein Coat of Trypanosoma brucei 
 
One of the main features of the T. brucei that raises interest between the 
scientific communities, is his capability of evading the host immune system, and 
thereby remains in circulation for months to years. This is achieved by antigenic 
variation of the parasite coat. The Trypanosoma brucei has a 15 nm Variant Surface 
Glycoprotein (VSG) coat that covers the entire cell, during the bloodstream form 
(Vickerman 1969). The VSG coat, as the name suggests, is composed by, 
approximately, 10 million copies of VSG molecules, and represents up to 10% of the 
total cell protein (Cross 1996).  
The VSG monomer consists of an exposed N-terminal domain, comprising 
about ! 350 residues, that contains the biologically relevant epitopes (Hsia et al. 1996) 
and a membrane-proximal C-terminal domain, of 50 to 100 residues, that is inaccessible 
to the antibodies (Johnson & Cross 1979; Schwede et al. 2011). The C-terminal is 
attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor 
(Ferguson et al. 1988). 
Over the course of the infection, the host immune system develops a response 
against the VSG expressed at that time, however this is inefficient in eradicating the 
entire parasite population, as some individuals have already switched their VSG 
(Vickerman 1978). The VSG coat also serves to protect less variable or even invariant 
surface proteins from immune effectors (Hutchinson et al. 2003). 
There are two more life cycle steps where the VSG is shed from the parasite 
surface: when all cells exchange the metacyclic VSG for a bloodstream form VSG, 
within a few days after entry into a mammalian host (Esser & Schoenbechler 1985); and 
when the trypanosome enters the tsetse midgut. The procyclic form stops expressing 
any VSG and starts to express another GPI-anchored glycoprotein, yet invariant, the 
procyclin (Figure 3). When the parasites re-enter the vertebrate host as metacyclic 
trypomastigotes, the expression of VSG is activated once again (Bülow et al. 1989). 
When the VSG coat is shed in the differentiation from stumpy bloodstream 
forms to procyclic forms, in the tsetse midgut, two forms of VSG were identified, in 
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vitro, within hours of the initiation of differentiation: one is full-length VSG protein that 
is cleaved from the cell surface by a GPI-phospholipase C (GPI-PLC) (Ziegelbauer et 
al. 1993) and the other, is a truncated VSG fragment released by proteolysis, by the 
major surface protease (MSP) (Bangs et al. 1997; Gruszynski et al. 2006). 
 
1.2.4 Major Surface Protease and Phospholipase C from Trypanosoma 
brucei 
 
There is a parasitic protozoa evolutionary related with T. brucei, that occurs as 
an extracellular form in the sand fly vector and as an intracellular form in their 
mammalian hosts macrophage, the Leishmania spp. These parasites contain a major 
surface zinc metalloprotease (MSP, also called GP63), which has been extensively 
studied. Among other function, this metalloprotease provides resistance to complement-
mediated lysis before Leishmania enters the macrophage, participates in the attachment 
and entry into the macrophage supporting survival in the macrophage after entry 
(Brittingham et al. 1995; reviewed in Yao et al. 2003). 
Previously, LaCount et al. reported the presence in the genome of the African 
trypanosome, of at least, three gene families (TbMSP-A, -B, and -C) encoding 
homologues of the GP63 found in Leishmania spp. The TbMSPs share about 33% 
sequence identity, positional conservation of 20 cysteines and 10 prolines, and a 
metalloprotease catalytic site motif, HEXXH, with Leishmania GP63, which suggests 
common three-dimensional features. All of these three families are expressed in 
bloodstream stage trypanosomes, but only TbMSP-B is found in procyclic stage. 
Although, they all are expressed in the bloodstream stage, the TbMSP-A mRNA is 
about twice as abundant as the TbMSP-B mRNA, which is four times more than 
TbMSP-C mRNA. The sequences from the three TbMSP share about 33% identity, and 
the major difference is in their termini. The TbMSP-A has an extended C-terminal 
region, rich in serines and glutamates, that was not seen in the other two, and finishes in 
a short hydrophobic segment. TbMSP-B has a hydrophobic tail in the C-terminal. 
TbMSP-C has a C-terminal region highly hydrophilic, rich in charged amino acids and 
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prolines, which indicates that it is not linked to a membrane via GPI anchor, unlike 
TbMSP-A and -B (LaCount et al. 2003). 
It has been shown that TbMSP is a surface-localized zinc metalloprotease, with 
60 kDa, that is expressed, mainly, in differentiating bloodstream to procyclic parasites 
and in established procyclic cells. This MSP, in concert with PLC, participates in the 
removal of the VSG coat when bloodstream stage trypanosomes differentiate to 




 double mutant cell line, failed to 
differentiate into the procyclic form, most VSG remaining in the cell surface. This cell 
line also exhibited an altered morphology: enlarged with multiple nuclei and 





, showed a delay in VSG loss, but they were still able to differentiate, which leads 
to the conclusion, that MSP and PLC act synergistically in the VSG loss during 
differentiation (Grandgenett et al. 2007). 
A further detailed analysis provides evidence that TbMSP-B and GPI-PLC 
expression is coordinately and inversely regulated during differentiation (Gruszynski et 
al. 2006). 
Another possible function of the MSP, it is related to the capacity of the 
Trypanosoma brucei in disrupting the blood-brain barrier and invade the central 
nervous system (CNS). It has been shown that the metalloproteases expressed on T. b. 
brucei bloodstream forms display hydrolytic activity on proteins like, gelatin, casein, 
and matrix proteins such as collagen (de Sousa et al. 2010). 
Trypanosoma brucei has also an endogenous PLC of 39-40 kDa anchored to 
GPI residue, this protein does not have a N-terminal signal peptide nor a trans-
membrane domain, it behaves as an integral membrane protein (Bülow & Overath 
1986; Fox et al. 1986; Carrington et al. 1989). It is capable of hydrolysing the GPI 
anchor of the VSG, releasing dimyristyl glycerol (Ferguson et al. 1985). This hydrolysis 
results in the conversion of the hydrophobic membrane form of VSG (mfVSG) to a 
water soluble VSG (sVSG), resulting then in the shedding of the VSG from the parasite 
membrane. This reaction can be detected immunologically by detecting an epitope 
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contained in the residue of the anchor attached to the VSG, the cross-reacting 
determinant (CRD) (de Almeida & Turner 1983; Zamze et al. 1988). 
GPI-PLC concentrates in the flagellar membrane, disposed in a patchy, linear 
array along the flagellar attachment zone and extending into the free flagellum and it 
remains in the same location, both before and after activation, which means that to 
cleave the GPI anchor of VSG it does not move from its location (Hanrahan et al. 2009; 
Sunter et al. 2013). 
The GPI-PLC is only present in metacyclic and bloodstream stages of the life 
cycle, procyclic trypanosomes are resistant to this protein, because it contains GPI 
anchors bearing an extra acylation on the inositol ring (Field et al. 1991). 
Although GPI-PLC does not act alone in the VSG release, as explained before, it 
is described as a virulence factor. In a cell line with the PLC gene deleted, the infection 
was able to proliferate, however the levels of parasitemia were lower when compared to 
a control cell line, and the survival times of the mice were longer (Webb 1997). 
GPI-PLC is unable to release VSG of another parasite, when expressed by one 
trypanosome only targets its own plasma membrane. Also, VSG is not the only protein 
cleaved by GPI-PLC, this protein also acts in other proteins of lower and higher 
molecular mass, like other GPI biosynthetic intermediates (Cardoso De Almeida et al. 
1999). 
The action of GPI-PLC can be inhibited by some sulphydryl reagents, like Zn
2+
 
and p-chloromercurylphenylsulphonic (Carnall et al. 1997). 
 
1.3 Immunobiology of African Trypanosomiasis 
 
 Being an extracellular parasite, T. brucei encounters both innate and adaptive 
immune response from the host. As soon as the parasite enters in the host bloodstream it 
encounters the innate immune system as first barrier. The first response of the host to 
control the first peak of parasitemia consists of classical activated macrophages which 
phagocyte antibody-opsonised parasites (Shi et al. 2004) and secret pro-inflammatory 
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and trypanotoxic molecules, such as Tumoral Necrosis Factor - alpha (TNF)-" and 
nitric oxide (NO) (Mabbott et al. 1994; Sternberg & Mabbott 1996; Kaushik et al. 2000; 
Pan et al. 2006). In addition, these macrophages can be activated by the trypanosome 
DNA (Desoxiribonucleic acid) (Harris et al. 2006) or by the GPI anchor of the VSG 
(Coller et al. 2003). 
Although initial inflammatory response is beneficial to the host at an early stage, 
a sustained inflammation can cause pathological disorders. Therefore, it is essential to 
reduce the inflammation, reducing the classical activated macrophages and, 
consequently, reduce the pro-inflammatory cytokines. In order to accomplish this, type 
II cytokines, like IL-4, IL-10 and IL-13 have to be secreted, so they can induce 
alternatively activated macrophages. These macrophages are involved in a longer 
survival of the host because they are more anti-inflammatory (Namangala et al. 2001). 
Thus, to facilitate the control of the parasitemia and the pathology, it is needed a shift 
from a type I inflammatory response, in an early stage, to a type II inflammatory 
response, in a later stage (Namangala et al. 2009). 
Another mediator responsible, not just, for the control of the parasite levels, but 
also for the development of the pathology, is TNF-" (Magez et al. 1999). During 
trypanosome infections, TNF is involved both in parasitemia control and infection 
associated pathology such as anaemia, neurological disorders, fever and cachexia during 
both human and animal trypanosomiasis (reviewed in Taylor & Mertens 1999). VSG 
was identified as major TNF inducing component in trypanosome-soluble extract 
(Magez et al. 1998). In addition, protection from neuroinflammatory pathology of 
sleeping sickness has been associated with the levels of IL-10 and IL-6 in the brain 
(Sternberg et al. 2005). 
Since this parasite is extracellular there is a dominant humoral response of the 
host. The activation of polyclonal B cells results in an increase in the number of B cells 
and an elevation in plasma immunoglobulin, mainly IgM (Hudson et al. 1976; Diffley 
1983). The successive parasitemia waves are a result of the specific antibodies directed 
against the epitopes of the VSG coat. These antibodies are able to opsonize the parasites 
making possible the efficient phagocytosis and destruction of the immune complexes, in 
the liver, by the macrophages (Shi et al. 2004; Pan et al. 2006).  
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Trypanosome infections are characterized by a drastic suppression of the 
immune responses, which makes the host more susceptible to opportunistic infections. 
During the AT/HAT infections there is an inhibition of the T cell proliferation due to 
down regulation of IL-2 production and expression of IL-2 receptor, which leads to the 
host immunosuppression (Sileghem et al. 1989; Darji et al. 1992). It is believed, that 
TNF also plays a role in the process of suppressing the immune system (Schleifer & 
Mansfield 1993). 
 
1.4 DNA vaccination 
 
Since the first description where it was shown for the first time that an 
intramuscular injection of a plasmid was able to induce protein expression in muscle 
cells (Wolff et al. 1990), DNA vaccines have been object of many interest. 
Followed this initial report on DNA vaccines there was a proliferation of studies 
from cancer (Buchan et al. 2005), to infectious virus diseases, most prominently HIV 
(Human Immunodeficiency Virus) (Hammer et al. 2013), hepatitis C virus (Frelin et al. 
2004) and cytomegalovirus (Kharfan-Dabaja et al. 2013), but also parasitic diseases are 
potential targets to DNA vaccination, like malaria (Wang et al. 1998), Chagas disease 
(Quijano-Hernández et al. 2013) and African trypanosomiasis (Silva et al. 2009; Lança 
et al. 2011). 
In order to create the plasmid, first the gene sequence of interest has to be 
generated, synthetically or by PCR, and then is enzymatically inserted into the multiple 
cloning region of the plasmid backbone, purified and delivered to the inoculation site. 
DNA vaccination is capable of inducing both, humoral and cellular immune responses 
(Figure 5). It starts when the optimized gene sequence is delivered, and the plasmid 
enters the nucleus of transfected local cells, such as myocytes (1) and antigen presenting 
cells (APCs) (2). Once this entry is completed, foreign antigens are generated as 
proteins, as a result of the expression of the plasmid-gene. These antigens become the 
subject of immune surveillance by the Major Histocompatibility Complex (MHC) class- 
I and -II molecules. APCs are able to present vaccine-derived endogenous peptides on 
  1. Introduction 
 
  17 
MHC-I molecules, which is followed either by direct transfection by the plasmid 
vaccine (2) or by cross-presentation of cell-associated exogenous antigens (3). 
Additionally, after the secretion of protein antigens that have been shed from 
transfected cells are captured and processed within the endocytic pathway, APCs 
mediate the display of peptides on MHC II molecules (4). Antigen-loaded APCs travel, 
via the afferent lymphatic vessel (5), to the draining lymph node, where they present 
antigenic peptide to naïve T cells, providing the necessary secondary signals to initiate 
an immune response and expansion of T cells (6), or instead, activation of B cells and 
antibody production (7). This activation is due to cytokines secreted by the CD4 T 
helper cells during cell-to-cell interaction with B cells, which is a response to peptide-
bound MHC molecules and co-stimulatory secondary signals. Once T cells are primed 
in the draining lymph node they can be restimulated and expanded, by the presentation 
of the peptide-MHC complexes, at the immunization site. The activation of both T and 
B cells, elicit specific immunity against the antigen encoded by the plasmid. These cells 
travel through the efferent lymphatic system and provide a surveillance system (8) 
(reviewed in Kutzler & Weiner 2008). 
Over the years there were some safety concerns about DNA vaccination: the 
potential to be integrated into cellular DNA, the development of autoimmunity and the 
possibility of antibiotic resistance. However, studies conform the safety of this class of 
vaccines. DNA vaccines tested did not shown relevant levels of integration into host 
cellular DNA, it typically occurs at lower rates than spontaneous mutation frequencies 
(Temin 1998; Manam et al. 2000; Ledwith et al. 2000). Considering the possible 
development of autoimmunity induced by DNA vaccines, studies made did not detect 
convincing evidence of autoimmunity (Le et al. 2000). With regards to antibiotic 
resistance, it is improbable that resistances emerge because the resistance genes 
contained in the plasmids are not commonly used to treat human infections. Although 
all of these concerns, DNA vaccination has been proven to be safe. And in order to 
respond to the concerns, the European Medicines Agency (EMA) and the US Food and 
Drug Administration developed guidelines on safety and testing DNA vaccines 
(Robertson & Cichutek 2000; Anon 2007). 
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In addition to this advantage, DNA vaccines are able to encode several types of 
genes and proteins, they are stable, ease to store and can be manufactured on a large 
















Figure 5: Schematic representation of the mechanism of action of DNA vaccines (Kutzler & Weiner 
2008). 
One of the disadvantages of DNA vaccination is the poor immunogenicity. In 
order to solve this problem, immunization techniques, nowadays, are changing and 
being improved. Electroporation is considered a promise as a second generation DNA 
vaccine technology for humans (Otten et al. 2004). This method consists on the 
application of an electrical pulse to the target tissue which disturbs membranes, leading 
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this way to an increase of cell permeability (Satkauskas et al. 2005). This approach 
expands DNA distribution in the injected muscles and uptake of DNA by myocytes 
which results in a higher efficiency of DNA vaccines (Dupuis et al. 2000), leading to an 
increase in the immune response and in the levels of expression (Hirao et al. 2008; 
Rosati et al. 2008; Vandermeulen et al. 2014). Other technique is the particle-mediated 
epidermal delivery, or particle bombardment, a needle-free DNA delivery technology 
that was developed as a physical gene transfer method to deliver DNA vaccines coated 
onto 1-3 µm gold beads into skin cells (reviewed in Yager et al. 2009; Wang & Lu 
2013). Unlike routine intramuscular injection, this technique does not need larger 
amounts of DNA to have the same, or even higher, cellular and humoral immune 
response (Deng et al. 2014). This, may be due to the fact that DNA is delivered directly 
into the host’s skin cells instead of in extracellular spaces (Roy et al. 2000). Another 
needle-free technique is high-pressure mediated delivery, it is similar to particle 
bombardment, forces a liquid through a small orifice under pressure to deliver the 
vaccine parentally (Mumper 2003; Graham et al. 2013). This technique, showed a 
higher immune response, when compared with approaches using needles or syringes 
(Graham et al. 2013), and it is being used in clinical trials of DNA vaccines to 
Ebolavirus and Marburgvirus, with positive results (Sarwar et al. 2014). 
One example of a noninvasive technique is a dermal patch, like DermaVir 
(Genetic Immunity). It has the vaccine antigens encoded in a plasmid DNA formulated 
into a nanoparticle that target specialized dendritic cells under the skin. A single 
DermaVir immunization is able to produce a specific immune response (Cristillo et al. 
2007; Jin & Kim 2014). 
 
1.5 The Virus-like particles 
 
Virus-like particles (VLP) are multimeric, sometimes multiprotein, 
supramolecular assemblages, geometrically well-defined, with diameters in the range of 
25-100 nm, lacking genetic material, that mimic the overall structure of the native 
virions. The fact that recombinant VLPs do not contain viral genetic material, offers a 
safe method for prophylactic vaccination (reviewed in Chroboczek et al. 2014). The 
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idea of using non-infectious virus particles to develop prophylactic human vaccines has 
been attractive, since the discovery of non-infectious hepatitis B virus (HBV) particles 
(Millman et al. 1969). 
Commonly, VLPs are more immunogenic than subunit or recombinant vaccines, 
and are able to stimulate the humoral and cellular immune system. VLPs have a 
multivalent display and a highly ordered structure that constitute the pathogen-
associated molecular pattern motifs (PAMPs). Since these motifs are, by and large, 
unique to microbial antigens, the mammalian immune system has evolved to respond 
vigorously to this arrangement of antigens. PAMPs are able to trigger the innate 
immune sensing mechanisms and can be recognized by Toll-like receptors (TLRs) 
(reviewed in Plummer & Manchester 2011). VLPs are able to induce a strong B-cell 
response by efficiently cross-linking the membrane associated immunoglobulin 
molecules that constitute the B-cell receptor, thanks to the correct display of the 
antigenic epitopes and the highly repetitive structure (reviewed in Grgacic & Anderson 
2006). VLPs are efficiently taken up by dendritic cells (DCs) for processing and 
presentation by MHC-II and for promoting DC maturation and migration, stimulating 
the innate immune system (Fifis et al. 2004; Gamvrellis et al. 2004). As native virus, 
VLPs can also be processed in the cytosol of DCs and are presented by MHC-I 
molecules to cytotoxic CD8
+
 T cells by the cross-presentation mechanism, which is 
essential for the clearance of intracellular pathogens and for the induction of a potent 
cytotoxic immune response (Murata et al. 2003; Win et al. 2011).  
Several VLP-based vaccines are already licensed. The first recombinant vaccine 




 (Merck), against HBV (Krugman 1982). 
The next recombinant VLP-based vaccine took 20 years to be licensed: Gardasil
®
 
(Merck) against human papillomavirus (HPV). According to a study by the US Centre 
for Disease Control and Prevention, thanks to this vaccine there was a reduction of over 
50% in HPV infection among teenagers (Markowitz et al. 2013). A second VLP-based 
HPV vaccine, Cervarix
®
 (GlaxoSmithKline), was licensed in the USA, almost 3 years 
after Gardasil
®
 (Deschuyteneer et al. 2014). 
Based on the structure of their parental viruses, VLPs can be divided in two 
categories: non-enveloped and enveloped. The non-enveloped VLPs, such as the 
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licensed HPV VLP vaccines, consist of one or more components of a vaccine target 
antigens displayed on the VLP surface as a fusion to a heterologous viral protein with 
the ability to self-assemble, and they do not include any host components. These VLPs 
can be produced in prokaryotic and eukaryotic cells. On the contrary, the enveloped 
VLPs consist in the host cell membrane with the integrated target antigens displayed in 
the outer surface (reviewed in Lua et al. 2014). 
VLPs are not just suitable as vaccines for homologous virus from which they are 
derived. Additionally, they can be used for the display of foreign antigens, in order to 
enhance their immunogenicity. Many soluble antigens have a poor immune response; 
this can be overcome by rendering them highly repetitive in a single particle. In this 
case, VLPs have two roles: they serve as scaffolds for presenting antigens derived from 
other pathogens in a suitable repetitive configuration, and as adjuvants to boost the 
immune response. An example of this kind of VLPs, is the new VLP-based vaccine for 
malaria, that includes a portion of the circumsporozoite protein of Plasmodium 
falciparum fused to the N-terminus of hepatitis B surface antigen (Rutgers et al. 1988) 
and is, already, in phase III of the clinical trial (Agnandji et al. 2012). 
It was recently described a VLP based on the Triatoma virus (TrV) (Querido et 
al. 2013; Sánchez-Eugenia et al. 2015; Rodrígues Aguirre & Guérin 2015). This virus 
infects Triatomine bugs, the vector of Trypanosoma cruzi, the ethiological agent of 
Chagas Disease (Grayson 2010). The native TrV particles are composed by a 30 nm 
icosaedral capsid, with no lipid envelop. Its capsid is made up of 60 copies of a 
protomer, consisting of the structural proteins VP1 (29.7 kDa), VP2 (28.4 kDa) and 
VP3 (31.8 kDa), and VP4 (5.5 kDa) lying within the capsid and in contact with the 
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2. Work Aims 
 
The main aims of the present work are: 
1- Cloning the genes MSP and PLC of the bloodstream forms of Trypanosoma 
brucei brucei in pVAX1 and pET28a; 
2- Use the plasmids MSPpET28a and PLCpET28a to express the recombinant 
protein of MSP and PLC in Escherichia coli; 
3- In silico analysis and design the antigenic epitopes as candidates to the VLPs. 
4- Use the plasmids MSPpVAX1 and PLCpVAX1 as model to the development of 
DNA vaccines against Trypanosoma brucei, determine anti-Trypanosoma brucei 
antibodies and identify native proteins with serum from immunized mice by DNA 
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3. Materials and Methods 
 
3.1 Animals and parasites 
 
All animals used in this work were obtained and maintained in the bioterium of 
the Instituto de Higiene e Medicina Tropical, Lisbon – Portugal. Female Balb/C mice, 
between 5 to 8 weeks old, were used in the experimental infection with T. brucei and in 
the DNA immunization protocols. The strain of Trypanosoma brucei brucei used in the 
experimental model was a GVR35 obtained from the Unidade de Clínica Tropical of 
the IHMT. 
 
3.2 Infection protocol of mice and total protein extract from Trypanosoma brucei 
brucei 
 
Mice were inoculated intraperitoneally with trypanosomes prepared by dilution 
of the frozen stabilate T. b. brucei GVR35 with PBS-glucose 20 mM pH 7.4. In order to 
obtain protein extract of T. b. brucei, blood from infected Balb/C was collected, by 
cardiac puncture, in syringes with heparin (B. Braun - Germany) as anti-coagulant. 
Then, 200 µL of PBS-glucose 20 mM pH 7.4, was added to the collected blood and 
submitted to purify bloodstream forms of the parasite using a gravity-operated DEAE-
cellulose chromatography column, previously equilibrated with PBS-glucose 20 mM 
pH 7.4 (Lanham & Godfrey 1970). To evaluate the presence of bloodstream forms in 
the resultant fractions of the chromatography procedure, they were monitored by 
conventional optical microscopy. The fractions containing parasites were centrifuged, 
during 10 minutes at 380g, the pellet was suspended with PBS, and then frozen at -
20ºC. When the samples were defrosted, a protease inhibitor was added. In order to 
determine the protein concentration of the extract, the Bicinchoninic Acid Protein Assay 
Kit (Sigma – USA) was used. 
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3.3 Obtaining genomic DNA from Trypanosoma brucei 
 
The blood from the infected mice was used to purify genomic DNA from T. 
brucei, using a commercial kit QIAamp
®
 DNA Blood Mini Kit (Qiagen – USA). After 
this step, the DNA concentration was determined by spectrophotometry at a wavelength 
of 260 nm. The DNA samples were used as template for the amplification assays of 
Trypanosoma brucei brucei genes of interest. 
 
3.4 Obtaining the gene sequences of Trypanosoma brucei 
 
Two T. brucei genes of interest were used as possible antigenic targets for the 
construction of DNA vaccine prototypes. The nucleotide sequences of these genes, 
named Major Surface Protease (MSP) and Phospholipase C (PLC), were obtained from 
GenBank
® 
from National Library of Medicine – National Center for Biotechnology 
Information (NCBI), Bethesda – USA, under the gene identification (GI) AY230807 
and XM_946646.1, respectively.  
 
3.5 Construction and acquisition of the primers used in the amplification of 
Trypanosoma brucei genes of interest 
 
To each gene of interest (MSP and PLC) a pair of primers were design to the 
terminal regions 5’ and 3’. Subsequent to this, these primers, commercially acquired 
from Thermo Electron Corporation (Germany), were used in the amplification assays 
with Polymerase Chain Reaction (PCR). 
As cloning strategy, was added to the extremities of each pair of primers the 
restriction sites to the enzymes NheI (GCTAGC) (Promega - USA) and BamHI 
(GGATCC) (Fermentas - Germany), used for the amplification of both, MSP and PLC 
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genes. The following table (Table 1) shows nucleotide sequences of the primers used in 
the PCR. 
Table 1: Nucleotide sequences used in the primer synthesis for the gene amplification from Trypanosoma 
brucei. 
Gene Primer sequence 
MSP 5’region (sense) 5’-GCTAGCATGACCCAACTGTTA-3’ 
MSP 3’region (antisense) 5’-GGATCCTCACATTTGACGAG-3’ 
PLC 5’region (sense) 5’-GCTAGCATGTTTGGTGGTGTA-3’ 
PLC 3’region (antisense) 5’-GGATCCTTATGACCTTGCGGT-3’ 
 
3.6 Polymerase Chain Reaction (PCR) 
 
The PCR assays were used for the amplification of the gene of interest from 
Trypanosoma brucei. To this end, the amplification reaction was optimized under the 
conditions described below (Table 2): 
Table 2: Mix constituents. 
Constituents Quantity 
Genomic DNA from Trypanosoma brucei 
brucei 
100 ng 
Primers 100 pmol each 
dNTPs 
25 mM of each nucleotide dATP, dCTP, 
dTTP and dGTP)(Stratagene, California – 
USA) 
MgCl2 (Bioline – Germany) 3 mM 
DNA Polimerase (BIOTAQ
TM
, Bioline – 
Germany) 
5 U 
Reaction buffer NH4 (Bioline – Germany) 5 µL 
Final volume with sterile water 50 µL 
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After mixing the above constituents, the parameters used for the reaction were 
established in a thermocycler (Bio-Rad - USA): an amplification cycle with a 
denaturation temperature of 94ºC for 2 minutes, the annealing temperature of the 
primers of 55ºC for 1 minute and 30 seconds, and a extension temperature of 72ºC for 2 
minutes, in a total of 40 amplification cycles. 
After the amplification reaction, the samples were mixed with a Loading buffer 
(Bioline – Germany), and then submitted to a 0,8% (w/v) agarose gel electrophoresis 
(Bioline – Germany) with a Tris-Acetate-EDTA (TAE) with ethidium bromide (Sigma- 
USA). 
The amplification products were then extracted from the gel and purified with a 
commercial kit, QIAquick Gel Extration Kit (Qiagen - USA). In order to determine the 
size of the amplified fragments, was used the molecular weight marker Hiperladder I
TM
 
(Bioline – Germany). 
 
3.7 Construction of DNA vaccine prototypes 
 
3.7.1 Plasmid construction 
 
All the vectors used in the immunization process were derived from the 
commercially available plasmid vector pVAX1 (2999 bp, Invitrogen - USA) (Figure 6), 
designed to be use in the development of DNA vaccines. This vector contains the 
human cytomegalovirus (CMV) immediate-early promoter, the bovine growth hormone 
(BGH) polyadenylation signal and a kanamycin resistance gene.  
The genes amplified by PCR were submitted to a cloning strategy in the plasmid 
pVAX1. In order to accomplish this, both, fragments and the plasmid vector pVAX1, 
were submitted to a digestion step (37ºC for 3 hours) with restriction enzymes (NheI 
and BamHI), followed by a dephosphorylation step of the plasmid, using the enzyme 
alkaline phophatase (Promega - USA), with the purpose of removing the phosphate 
group in the 5’ region. The products from de enzymatic digestion, were, then, submitted 
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to a 0.8 % (w/v) agarose gel electrophoresis and the fragments were extracted from the 
gel and purified by QIAquick Gel Extraction Kit (Qiagen – USA). The products of this 
purification were cloned. To accomplish this, the enzyme DNA ligase (Promega - USA) 










Figure 6: Schematic representation of the plasmid pVAX1 (Invitrogen 2002). 
 
3.7.2 Bacterial transformation 
 
Plasmid DNA was added to competent cells, Escherichia coli DH5" cells, and 
submitted to a heat shock. First, the mixture was kept on ice for 30 minutes, then heated 
at 42ºC during 1 minute, and, immediately after, cooled down on ice for 2 minutes. The 
mixture was placed in 1 mL of LB Broth (Sigma - USA) medium and incubated for 40 
minutes to one hour at 37ºC. Then, the culture was centrifuged at 855g for 5 minutes, 
the resultant pellet was suspended and placed on LB/Agar (Sigma – USA) plates 
containing 30 #g/mL
 
(w/v) kanamycin for selection of transformed E. coli colonies and 
was incubated overnight. 
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Plasmid DNA used in the immunization process was prepared from 250 mL of 
E. coli DH5" in 20 g/L of LB medium with 30 #g/mL
 
(w/v) of kanamycin (Bioline - 
UK), overnight at 37ºC in an orbital shaker.  
 
3.7.3 Plasmid Purification 
 
Plasmid purification was performed by two different techniques, taking into 
account the quantity of plasmid needed: by standard alkaline lysis followed by 
hydrophobic interaction chromatography (HIC) (Diogo et al. 2000), when higher 
amounts of plasmid were needed, for example for the immunizations; and when lesser 
amounts were needed, was used the ISOLATE II Plasmid Mini Kit (Bioline - UK). 
Initially, to perform the alkaline lysis, the inoculum was centrifuge at 3000g for 
15 minutes at 5ºC. After discard the supernatant, was added 8 mL of solution P1 (in 
section 7), 8 mL of solution P2 (in section 7) and incubated for 5 minutes at room 
temperature, and then 8 mL of solution P3 (in section 7) and incubated for 5 minutes in 
ice. After all the solutions were added, the mixture was centrifuged for 30 minutes, at 
18000g. The supernatant was transferred to a new tube, and centrifuged one more time, 
in order to remove all the floating material. The clean supernatant, was then passed to a 
new tube and was added 0.8 of the final volume of isopropanol (Panreac – Germany), 
and cooled down at 4ºC overnight. 
The hydrophobic interaction chromatography, started with a centrifugation at 
18000g, during 30 minutes, at 5ºC. After the centrifugation, the pellet was washed with 
2 mL of ethanol at 70%, in a way, that just the DNA stays undissolved. Another step of 
centrifugation, in the previous conditions was performed, and the supernatant was 
discarded and the pellet was left to dry. Then it was suspended in 500 µL of Solution 1 
(in section 7) and placed in microtubes of 1.5 ml with 0.16 g of ammonium sulphate, 
and centrifuged at 9503g for 5 minutes. The 500 µL of sample were placed in the 
column, previously equilibrated with Solution 2 (in section 7). After the column stopped 
dripping, first, 3 mL of Solution 2 was added, and then 2 mL. So, the final volume of 
this step was 2 mL. 
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In order to remove the salt from the HIC step, a gel-filtration was performed. 
The resulting 2 mL were added to a second column, previously equilibrated with PBS 
1X. Then, 1.5 mL of PBS 1X was added, to bring down the plasmid, and finally, 3 mL 
of the same solution to recover the plasmid. When the plasmid was recovered, the same 
volume of isopropanol was added and left overnight at 4ºC. The last step of the 
purification consists of a centrifugation for 30 minutes, at 18000g. The supernatant was 
discarded and the pellet suspended in 1 mL of PBS 1X. The optical density of the 
purified plasmids was measured at 260 nm. To confirm the prevalence of the super 
coiled form of the plasmid, the samples were submitted to a 1% (w/v) agarose gel 
electrophoresis. The plasmids used in the immunization process were characterized by 
automated sequencing (STABVIDA, Lisbon – Portugal) and by a restriction analysis. 
 
3.8 Subcloning the genes into plasmid pET28a 
 
 In order to express the recombinant proteins MSP and PLC in E. coli, was used 
the pET28a plasmid vector (5369 bp, Novagen - Germany) (Figure 7), designed to be 
use in the expression of recombinant proteins in Escherichia coli. So, to achieve this, it 
was needed a subcloning step. The MSPpVAX1 and PLCpVAX1 plasmids were 
digested (37ºC for 3 hours) with the restriction enzymes NheI and BamHI. The pET28a 
plasmid was also submitted to a double digestion in the same conditions. 
As soon as the digestion is completed the products were submitted to a 0.8% 
(w/v) agarose gel electrophoresis and the fragments with the genes were extracted from 
the gel and purified with the QIAquick Gel Extraction Kit (Qiagen – USA). The sub-
cloning process was accomplished as described in the section 3.7. The sub-cloned 
plasmids were characterized by automated sequencing (SECUGEN - Madrid) and by a 
restriction analysis with NheI and NotI (Promega - USA), at 37ºC for 3 hours. 
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Figure 7: Schematic representation of the plasmid pET28a (Novagen 2003). 
 
 
3.9 Immunization Protocol 
 
The Balb/C mice were divided in 5 groups, with 3 animals per group, and each 
was immunized subcutaneously with 100 µg of the vaccine candidates, Table 3.  There 
was a control group that was injected with the same amount of pVAX1. In the groups 1 
to 4, the plasmids were eluted in PBS 1X pH 7.4, and the group 5, in a solution of 10 
mg/mL of nanoxylan. This is a nanoformulation that is derived from brown seaweed: 
Spatoglossum schröederi. It has been proven to have antiproliferative, anti-adhesive, 
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Table 3: Vaccine composition per group. 




G4 MSPpVAX1 + PLCpVAX1 
G5 MSPpVAX1 + PLCpVAX1 
 
It was used three immunization steps and six blood collection, as demonstrated in the 
following figure. 
Figure 8: Immunization protocol.  
 
 
3.10 Harvesting the serum of the immunized mice 
 
The blood samples of the immunized mice were collected at 6 different time 
points. The blood was collected through terminal tail. 
After the blood was collected, it was placed at 37ºC for 30 minutes and then at 
4ºC for 1 hour. To obtain the serum, the samples were centrifuged at 3421g for 10 
minutes, and, finally, the serum was stored at -20ºC. 
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3.11 Determination of anti-Trypanosoma brucei antibodies by ELISA in mice 
immunized by DNA vaccine 
 
Total IgG antibodies anti-T. b. brucei were titled by Enzyme-Linked 
Immunosorbent Assay (ELISA), using serum samples from immunized mice. First, 96-
well microplates (Costar - USA) were coated with 100 ng/well of total protein extract 
from Trypanosoma brucei brucei dissolved in bicarbonate buffer pH 8.5 (in section 7), 
overnight in moist atmosphere at 4ºC. The microplates were, then, washed three times 
with 0.05% Tween 20 (Sigma-Aldrich - USA) in PBS 1X and blocked for one hour with 
2% casein (w/v) (Sigma – USA) in PBS 1X, at room temperature. After three wash-ups, 
serial dilution of serum from immunized mice in antibody buffer (0,4% casein in PBS 
1X) added to the plates and incubated for one hour at room temperature. The 
microplates were washed five times and, then incubated, for 1 hour, with horseradish 
peroxidase (HRP)-conjugated antibodie: "-mouse IgG (Sigma - USA) diluted 1:4000. 
After another step of five wash-ups, it was added the substrate solution: 10 mL of citrate 
buffer pH 5.0 (in section 7), 10 mg of OPD (o-phenylenediamine dihydrochloride) 
(Sigma - USA) and 10 µL of H2O2 30 % (v/v) (Sigma-Aldrich - USA), for 30 minutes at 
room temperature and in the dark. To stop the reaction, after the 30 minutes, 50 µL/well 
of 4N sulphuric acid was added, and the optical density was measured at 490 nm. 
 
3.12 Expression of the recombinant MSP and PLC proteins in Escherichia coli 
 
Cells BL21 (DE3) (Novagen – Germany), BL21 (DE3) pLys (Novagen – 
Germany), Rosetta (DE3) (Novagen – Germany) and Origami2 (DE3) pLys (Novagen – 
Germany) from E. coli, were transfected with MSPpET28a and PLCpET28a and 
inoculated with LB medium at 37ºC and with agitation, until reaching, approximately, 
0.8-1 optical density (600 nm). An aliquot of 200 µL was, then, placed in a new LB 
medium and the expression of the respective recombinant proteins were induced by 
adding 5 #L of 0.5 mM IPTG (Bioline – UK) in different time-points and at different 
temperatures, in agitation. The remaining non-induced cells were used as negative 
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control. The cells were centrifuged at 6000g for 10 minutes at 4ºC, and the pellet was 
suspended in PBS 1X pH 7.4. Subsequently, SDS-sample buffer 1:1 (v/v) was added to 
the samples, and they were reduced by putting them at 100ºC for 7 minutes. After the 
reduction step, the samples were submitted to a sodium dodecyl sulfate 10% (w/v) 
polyacrylamide gel electrophoresis (SDS-PAGE) and then stained with Comassie 
Brilliant Blue. 
 
3.13 Immunological identification of native MSP and PLC proteins of bloodstream 
forms of T. b. brucei with serum from immunized mice 
 
In order to confirm the presence of the proteins used in the immunization 
protocol, the Western Blot technique was used. 
The total protein extract of Trypanosoma brucei brucei was submitted to a SDS-
PAGE. 
The gels were blotted onto nitrocellulose membranes (Whatman Protra
 
- 
Germany) by electric transference at 4ºC in blotting buffer, overnight. The membranes 
were washed two times, for 10 minutes, with a washing buffer (0.05% Tween 20 in 
TBS 1X) and then blocked with a blocking buffer (3% powder milk (w/v) in TBS 1X) 
for 1 hour at room temperature. Afterward, the membranes were washed five times, for 
1-2 minutes, and incubated with the serum from the immunized mice diluted in a 
antibody buffer (0.1% powder milk (w/v) in TBS 1X) 1/10 (v/v) for 1 hour at room 
temperature on orbital shaking. The membranes were washed and incubated, for 1 hour, 
with horseradish peroxidase (HRP)-conjugated antibodie: "-mouse IgG diluted 1:4000. 
After this, the membranes were washed five times with washing buffer, in orbital 
shaking. The development solution, DAB (3,3’ – Diaminobenzidine tablets – 
SigmaFast, Sigma-Aldrich - USA) 0.5 mg/mL in TBS 1X with 0.02% H2O2, was added 
and incubated at room temperature until the color development (2-10 minutes). The 
reaction was stopped with deionized water and the membrane was left to dry. 
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3.14 Parasite challenge of the immunized mice 
 
 The previously immunized mice were infected with 500 parasites/animal of the 
infecting form of Trypanossoma brucei brucei, by intraperitoneal injection. The 
infection took place 92 days after the last immunization. The survival of the infected 
animals was registered daily. The number of parasites in the blood was monitored on 
days 5, 8, 10, 12 and 15 post-infection, by smear stained by Giemsa. The method used 
to count the parasites was adapted from Luz et al. 2005: were counted 25 fields per 
slide and then was made an estimate to 100 fields.   
 
3.15 Analysis in silico of MSP and PLC genes 
 
 With the resulting sequences from automated sequencing, a brief analysis in 
silico was made, to collect some information about the proteins being used. 
 In order to achieve this, the resulting sequences were treated with the software 
Geneious
®
 (version 8.1.2) (Kearse et al. 2012). Then, a BLAST was made, with this 
step was obtained the protein sequence. Using ProtParam (Gasteiger et al. 2005) from 
Expasy, it was possible to obtain the molecular weight and the theoretical pI, which is 
needed to separate the proteins in a polyacrylamide gel using isoelectric focusing. As 
mentioned before, section 1.2.4, both proteins are anchored to GPI, so the tool GPI-
Predictor (Eisenhaber et al. 1998; Sunyaev et al. 1999; Eisenhaber et al. 1999; 
Eisenhaber et al. 2000) was used, in order to verify if this happened with the proteins 
used here. Ultimately, with TMHMM 2.0 (Sonnhammer et al. 1998; Krogh et al. 2001), 
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3.16 Design of the antigenic epitopes as candidates to the VLPs 
 
The process of designing the antigenic epitopes, using the MSP and PLC from 
T. b. brucei, as candidates to the VLPs was a four-step process. In this process, was 
used the crystallographic structure of TrV (Triatoma Virus) (Squires et al. 2013). 
The first step consisted of bibliographic research, in order to obtain as much 
information as possible about the proteins used, like, the tertiary structure and existence 
of epitopes. The tertiary structure was searched in the Protein Data Bank (Berman et al. 
2000) using the keywords: "Major Surface Protease", "MSP", "Trypanosoma brucei", 
“PLC” and “Phospholipase-C”. 
In the second step, the insertion region of the epitopes was selected from the 
atomic structure of the TrV. To complete this step, first an analysis of the tertiary 
structure, by the PyMOL software (Schrodinger LLC 2010), was made, in order to see 
where the epitopes could be located in the protein and a qualitative analysis of the 
exposure to the solvent of the epitopes. The ASA-View (Ahmad et al. 2004) made the 
quantitative analysis of this exposure. The exposure is a residue characteristic that 
measures the accessibility to the solvent. The epitopes should be exposed in order to be 
recognized by the immune system (Joshi et al. 2013). 
The third step of the process was the construction of the atomic model of the 
chimerical particle, using a software called Coot (Emsley & Cowtan 2004). In this step, 
the amino acids from the native TrV structure were changed by the amino acids of the 
epitopes. 
The fourth step consisted of determining how the changes made by the insertion 
of the epitopes into the TrV native structure changed both the epitopes and the TrV 
properties. In order to accomplish this, all the structures (protein, native TrV and 
mutated TrV) were carefully analyzed and compared between each other. There were 
three criteria compared: exposure, salt bridges and disulphide bond. The salt bridges 
were analyzed by ESBRI (Costantini et al. 2008) and VMD (Humphrey et al. 1996); 
and to analyze the disulphide bonds was used a script from www.pymolwiki.org. 
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An additional software, UCSF Chimera (Pettersen et al. 2004), was used in 
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4. Results and Discussion 
 
4.1 Restriction Analysis of the plasmids 
 
4.1.1 Restriction Analysis of the plasmids cloned in pVAX1 
 
 The previously cloned plasmids MSPpVAX1 and PLCpVAX1 were submitted 
to a restriction analysis with NheI and BamHI, as explained in section 3.7.3, and 
analyzed by a 1% (w/v) agarose gel electrophoresis. The Figure 9 shows the results 
from the restriction analysis of the cloned plasmids.  
 
Figure 9: Restriction analysis of the genes MSP and PLC cloned in pVAX1. M- Marker HyperLadder™ 
I (Bioline – UK); 1- pVAX1; 2- PLCpVAX1 digested with BamHI; 3- PLCpVAX1 digested with NheI 
and BamHI; 4- MSPpVAX1 digested with BamHI; 5- MSPpVAX1 digested with NheI and BamHI. 
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In the well 1 it is shown the plasmid pVAX1 (! 3.0 kb) without any gene or 
enzyme restriction. 
The restriction of the PLCpVAX1 suggests the cloning of the fragment PLC (! 
1.1 kb) into the pVAX1 plasmid, generating a fragment of approximately 4.1 kb when 
digested with BamHI (well 2). This suggestion is reinforced by the restriction analysis 
with NheI and BamHI enzymes (well 3), because it shows two fragments: the first one 
of ! 3.0 kb (pVAX1) and ! 1.1 kb (PLC). 
When the plasmid MSPpVAX1 was digested with BamHI (well 4) a fragment of 
approximately 4.7 kb was present, suggesting the insertion of the fragment MSP (! 1.7 
kb) into the pVAX1 plasmid (! 3.0 kb). When the MSPpVAX1 was digested with 
BamHI and NheI (well 5), two fragments appeared: one of ! 3.0 kb, that corresponds to 
pVAX1 and another of ! 1.7 kb that corresponds to MSP. 
After the restriction analysis, both plasmids (MSPpVAX1 and PLCpVAX1) 
were submitted to an automated sequencing to determine the gene sequence and to 
compare them with the original sequences. 
 
4.1.2 Restriction Analysis of the plasmids sub-cloned in pET28a 
 
The plasmids MSPpVAX1 and PLCpVAX1 were submitted to a sub-cloning 
step: the genes MSP and PLC were sub-cloned into the pET28a plasmid, as referred in 
section 3.8. After this, both plasmids were submitted to a restriction analysis, seen in 
Figure 10. The main aim of this sub-cloning step was to express the recombinant 
proteins MSP and PLC, in prokaryotic cells. 
When the plasmid MSPpET28a was digested with HindIII (well 1) a fragment of 
! 7.0 kb was present, suggesting the insertion of the fragment MSP (! 1.7 kb) into the 
plasmid pET28a (! 5.3 kb). This is supported by the restriction analysis with NheI and 
NotI enzymes (well 3), which shows the presence of two fragments: the first one, of ! 
5.3 kb, that corresponds to pET28a; and the second, of ! 1.7 kb, corresponding to the 
fragment MSP. 
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The restriction analysis of the PLCpET28a also suggests the cloning of the 
fragment PLC (! 1.1 kb) into the pET28a plasmid, which generated a fragment of 
approximately 6.4 kb when digested with HindIII (well 2) and two fragments of ! 5.3 













Figure 10: Restriction analysis of the genes MSP and PLC cloned in pET28a. M- Marker 
HyperLadder™ I (Bioline – UK); 1- MSPpET28a digested with HindIII; 2- PLCpET28a digested with 
HindIII; 3- MSPpVAX1 digested with NheI and NotI; 4- PLCpVAX1 digested with NotI and NheI. 
 
After the restriction analysis, both plasmids (MSPpET28a and PLCpET28a) 
were submitted to an automated sequencing to determine the gene sequence and to 
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4.2 Analysis by automated sequencing of the MSP and PLC genes in pVAX1 and 
pET28a 
 
 After the restriction analysis, the plasmids were analyzed by automated 
sequencing to determine the nucleotide sequence from the MSP and PLC genes from T. 
brucei. 
 The results of the sequencing are shown bellow (Table 4), and show the identity 
between the genes cloned in both plasmids (pVAX1 and pET28a) and the original 
sequences of MSP and PLC from the GenBank
®
, AY230807 and XM_946646.1, 
respectively. 
 
Table 4: Alignment of the sequencing results with the original sequence from the MSP and PLC genes 
from Trypanosoma brucei brucei. 
Plasmid Primer Sequenced region  Identity (%) 
MSPpVAX1 T7 fwd 1083 bp 99 
MSPpVAX1 BGH rev 543 bp 99 
PLCpVAX1 T7 fwd 1176 bp 99 
PLCpVAX1 BGH rev 689 bp 99 
MSPpET28a T7p 1296 bp 99 
MSPpET28a T7t 1303 bp 99 
 
 The previous table does not show the results from automated sequencing of the 
plasmid PLCpET28a because they came back unclear and was impossible to analyze 
them. 
Together, the results from the restriction analysis and the sequencing, confirm 
the cloning, the identification and the characterization of the plasmids constructed in 
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4.3 Purification of the plasmids used in the immunization protocol 
 
After cloning, identification and characterization, the MSPpVAX1 and 
PLCpVAX1 were produced in Escherichia coli DH5" cells, and then purified by 
hydrophobic interaction chromatography and gel filtration, according to Diogo et al. 
2000. 
In order to obtain a sufficient amount of plasmid to immunize all of the mice 
three times, several processes of production and purification were needed. In the end, a 
pool with all the produced and purified plasmid was made, and some laboratory 
parameters were observed (Table 5), such as concentration and purity of the plasmid, 
determined by optical density with a wavelength of 260 and 280 nm.  
 
Table 5: Parameters of the plasmids used in the immunization protocol.  
Plasmid Concentration (µg/mL) Ratio 260/280 nm 
pVAX1 775 1.733 
MSPpVAX1 600 1.282 
PLCpVAX1 575 1.256 
 
 
4.4 Determination of anti-Trypanosoma brucei brucei antibodies in mice 
immunized by DNA vaccine 
 
 As described, previously, in section 3.9, 15 Balb/C mice were divided in 5 
groups of 3 mice per group. Each mouse was immunized three times intramuscularly 
with 100 µg of plasmid. There were six different time points of serum collection (day 
29, 43, 50, 64, 71, 113 post-immunization), after each one of them the samples were 
tested by ELISA, in order to determine the anti-Trypanosoma brucei brucei antibodies 
production, therefore, the humoral response. A total protein extract from T. brucei 
brucei was used as an antigen source. The results of this assay, in figure 11, are 
presented as a relation between time of immunization and optical density. 
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 The genes used to develop the vaccines (MSP and PLC) were selected due to the 
fact that both are expressed during the bloodstream forms of the parasite, they act 
synergistically to the loss of VSGs during differentiation from bloodstream form to 
procyclic form and consequently to the evasion of the immune system (Carrington et al. 
1998; Grandgenett et al. 2007; Hanrahan et al. 2009). There are several works 
suggesting that the injection of plasmids encoding different proteins from T. b. brucei, 
specifically ISG and nTSA, results in humoral response and partial immune protection 
(Silva et al. 2009; Lança et al. 2011). 
 The results presented in Figure 11, confirm the production of IgG antibodies 
anti-T. b. brucei. The dilution of serum used in this assays was 1:100 (v/v). A pattern of 
response can be observed: after each immunization the optical density decreases, 
meaning there is an adaptation period. After this, the antigen becomes more 
immunogenic due to the activation of B-cells, resulting in an increase of optical density. 
Finally, because of the half-life period of the antibodies there is a decrease in the 
antibodies titre. A higher and faster response was observed after the second 
immunization, due to the presence of memory cells. However, the titre values should be 
higher than the control (G1), in order to be considered as humoral response. The groups 
where this characteristic is more evident are the ones immunized with PLCpVAX1 (G3) 
and with MSPpVAX1+PLCpVAX1+nanoxylan (G5). 
Taking into account that the two groups immunized with both plasmids (G4: 
MSPpVAX1+PLCpVAX1 and G5: MSPpVAX1+PLCpVAX1+nanoxylan) have the 
same components and that the one with nanoxylan has a higher immune response than 
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Figure 11: IgG anti-Trypanosoma brucei brucei humoral immune response elicited by DNA vaccination. 
 
 
4.5 Immunological identification of native and recombinant Trypanosoma brucei 
brucei proteins from immunized mice 
 
 In order to identify immunologically recombinant MSP and PLC proteins, 
competent cells from E. coli had to be transfected with the plasmids PLCpET28a and 
MSPpET28a. The technique specified in section 3.12, was tried at different conditions: 
different temperatures (25ºC, 28ºC and 37ºC) and different times of induction with 
IPTG (0h, 1h, 2h, 3h and 4h); and then, submitted to SDS-PAGE and stained with 
Comassie Brilliant Blue. However, the proteins were not expressed in any of these 
conditions. Several works report the difficulty of producing membrane proteins due to 
their partially hydrophobic surfaces, flexibility and lack of stability. Moreover, it has 
been proven that the expression of functional eukaryotic membrane proteins in 
prokaryotic hosts is very difficult, due to a number of factors: the difference of lipid 
composition between bacterial and eukaryotic membranes, which could lead to an 
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post-translationally, the eukaryotic proteins. Nowadays there is a large number of 
expression systems that have been proven to work better with eukaryotic membranes: 
yeasts, insect cells among others (reviewed in Loll 2003; Carpenter et al. 2008). 
In the Figure 12, is represented one of the attempts to express the recombinant 
proteins, where the nTSA (wells 1-4) served as positive control. As can be seen, MSP 
(wells 5-8) and PLC (wells 9-12) were not expressed. 
 
Figure 12: Results of the SDS-PAGE to test the expression of the recombinant proteins. 1- Negative 
control of the expression of nTSA; 2- Expression of nTSA induced with IPTG at 0h; 3- Expression of 
nTSA induced with IPTG at 2h; 4- Expression of nTSA induced with IPTG at 3h; 5- Negative control of 
the expression of MSP; 6- Expression of MSP induced with IPTG at 0h; 7- Expression of MSP induced 
with IPTG at 2h; 8- Expression of MSP induced with IPTG at 3h; 9- Negative control of the expression of 
PLC; 10- Expression of PLC induced with IPTG at 0h; 11- Expression of PLC induced with IPTG at 2h; 





The next step was to identify native MSP and PLC proteins from serum from the 
immunized mice. 
 First, to select the optimal concentration of total protein extract for a better gel 
resolution and visualization of the proteins from T. b. brucei, this one was submitted to 
a SDS-PAGE with different amount of proteins extract (Figure 13). The amount of 
protein extract used was 10x10
3
 µg/well. 
  4. Results and Discussion 
 


















Figure 13: Electrophoretic profile of total protein extract of Trypanosoma brucei brucei in 
polyacrylamide gel electrophoresis and stained with Comassie Brilliant Blue. Samples 25µL to 2,5 
µL/well: amount (in volume) of protein extract with 500 µg/µL. 
 
After the optimal amount of protein extract had been selected the parasite extract 
was submitted to a Western Blot technique, in order to confirm the presence of the 
proteins being used in the immunization protocol. With all the serums collected from 
the immunized mice, a pool was made per group. The dilution of serum used in this 
assays was 1:10 (v/v). 
According to the literature and the, analysis in silico (Section 4.7, Table 6), it 
was expected that the serum from immunized mice with MSPpVAX1 presented a band 
with ! 60 kDa (Grandgenett et al. 2007) and, in the case of, PLCpVAX1 the molecular 
weight was ! 40 kDa (Hereld et al. 1986; Carrington et al. 1998). As can be seen in 
Figure 14, the results were not the expected: the molecular weights do not correspond 
with the ones from the literature. The presence of bands in the control group (G1) could 
be a result of non-specific reactions (cross-reactions with non-specific antibodies of 
Trypanosoma brucei brucei). Another feature that is relevant to discuss, is the fact that, 
although, several dilution of the serum were tried, none of them resulted in bands with 
high intensity. This results together with the ones from the ELISA, suggest that the 
proteins are being expressed in low levels. 
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Figure 14: Immunodetection of antibodies in pools of serum of the immunized mice. 1- G1: pVAX1; 2- 
G2: MSPpVAX1; 3- G3: PLCpVAX1; 4- G4: MSPpVAX1+PLCpVAX1; 5- G5: 
MSPpVAX1+PLCpVAX1+nanoxylan; 6- Positive control (serum from an infected mice with 24 DPI); 7- 
Polyclonal; 8- Negative control; MW- Molecular weight marker HyperPAGE
®
 (Bioline – Germnay). 
 
 
4.6 Challenge assays of immunized mice 
 
 In order to test the efficiency of the vaccines, the previously immunized mice, 
were challenged with Trypanosoma brucei brucei. This assay consisted in the 
intraperitoneally injection of 500 parasites/animal, 149 days after the first 
immunization. After the infection, the animals were monitored daily, smears were 
peaked on days 5, 8, 10, 12 and 15 post-infection, and the survival rate was evaluated 
and compared between each group. 
  4. Results and Discussion 
 
  50 
As can be seen in Figure 15, the infection protocol was successfully executed: 
parasites appear in circulation 5 days post-infection (DPI), and the pattern of infection is 
similar to the one presented in section 1.2.1 (Figure 3), distinctive feature of the 
Trypanosoma brucei infection. Although the differences between groups are not that 
evident, a small difference can be noticed: in G3 and G5, the parasitemia peak is lower 
than in the other groups; and G3 reaches the lowest level of parasitemia at 10 DPI. 
 
Figure 15: Parasite concentration at days 5, 8, 10, 12 and 15 post-infection with Trypanosoma brucei 
brucei. 
 
In Figure 16, it can be observed that, all animals, except one from the control 
group, survived until, at least, day 23, and all groups present deaths after 25 DPI. The 
control group presents 100% of mortality after 27 DPI. 
At 27 DPI, the groups presented different mortality rates: G2 and G4 had a 
mortality of 67%; G3 presented 100% of mortality; and the mortality of G5, was 33%. 
The groups G4 and G5 present the highest survival rates, although with slight 
differences: they reached 67% of mortality at 26 and 28 DPI, respectively. However one 
of the mice from G4 survived longer (until day 32). 
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Nevertheless, the groups immunized with the prototype vaccines did not show 
strong resistance to the infection, when compared with the control group and with some 
other works in this field, but they survived longer than in a normal infection (without 
vaccine) (Silva et al. 2009; Lança et al. 2011). This can be explained with the fact that 
the pDNA was not strong enough to cause a protective effect on immunized mice or 
because the challenge assay was done too far apart from the immunization. 
Figure 16: Survival of immunized mice after challenge with Trypanosoma brucei brucei. 
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4.7 Analysis in silico of MSP and PLC genes 
 
 The resultant sequences from the sequencing with both primers were put 
together with the help of the software Geneious
®
 (version 8.1.2) (Kearse et al. 2012). 
Then a BLAST was made, in order to determine the sequence most similar to the ones 
in study and to determine the protein sequence. These results, then allowed the search 
for additional information about the proteins used, such as molecular weight, theoretical 
pI, "position" in the cell, the GPI-modification site (Table 6). The zinc motif domain of 




Table 6: Results of an analysis in silico of MSP and PLC. 


















  4. Results and Discussion 
 
  53 
4.8 Design of the antigenic candidates to the VLPs 
 
As mentioned in section 1.5, in this work was used a virus-like particle based on 
TrV, which is made of 60 copies of a protomer. This protomer is composed by three 
proteins: VP1, VP2 and VP3 (Figure 17). 
Figure 17: Representation of the capsid of TrV, with the capsid proteins of one protomer highlighted: 
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In order to start the design of the VLP, the first step, as was said before in 
section 3.16, was the search for possible existence of a tertiary structure of both 
proteins, MSP and PLC. However, this was not found, because none of the proteins had 
the tertiary structure resolved. Therefore, was searched for the same proteins but in 
other organisms, and nothing was found. The alternative was to search for a homolog 
protein in other organism. So, for the MSP, a homolog protein was found, the GP63 of 
Leishmania major (Schlagenhauf et al. 1998). This protein has an identity of 32% with 
the sequence of the MSP used in this work and both proteins are zinc metalloproteases 
from organisms from Trypanosomatidae family and the Kinetoplastida order. Besides, 
GP63 already has antigenic epitopes described, and, as said in the section 1.2.4, the 
GP63 share positional conservation of 20 cysteines and 10 prolines, with Trypanosoma 
brucei MSP, which suggests common three-dimensional features (LaCount et al. 2003). 
Nevertheless, there was nothing found for the PLC, so this protein could not be used. 
After selecting the protein, a bibliographic search for epitopes was done.  
Among all the epitopes found, only three epitopes were chosen, based on their identity 
with the MSP used in this work. In Figure 18 is shown the tertiary structure of GP63 
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Figure 18: Representation of the epitopes on the tertiary structure of the GP63, ribbon model (left) and 
surface model (right). The figure with surface shows how the epitopes are exposed. Epi-1 is represented 
in red; Epi-2 is represented in green; Epi-3 is represented in orange; blue represents the common region 
between Epi_1 and Epi-2. Images obtained using PyMOL (Schrodinger LLC 2010). 
 
The three epitopes chosen were: Epi-1 (Figure 19), Epi-2 (Figure 20) (Russo et 
al. 1993) and Epi-3 (Figure 21) (Elfaki et al. 2012). Table 7 shows the relevant 
information about the three epitopes. 
 










Epi-1 254-269 YDQLVTRVVTHEMAHA 60 
"-helix 
and loop 
Epi-2 259-274 TRVVTHEMAHALGFSVG 69 
"-helix 
and loop 
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Figure 19: Detailed view of the most exposed amino acids of Epi-1 in the GP63. Images obtained using 
UCSF Chimera (Pettersen et al. 2004). 
 
Figure 20: Detailed view of the most exposed amino acids of Epi-2 in the GP63. Images obtained using 
UCSF Chimera (Pettersen et al. 2004). 
The tertiary structure of Epi-3 in the GP63 has missing residues due to an 
uninterpretable weak electron density (Schlagenhauf et al. 1998). However, these 
residues were considered as highly exposed to the solvent (in Attachments F-H) because 
their supposed position and due to the weak electron density frequently being related to 
high fluctuation. 
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Figure 21: Detailed view of the most exposed amino acids of Epi-3 in the GP63. Images obtained using 
UCSF Chimera (Pettersen et al. 2004). 
 
When all the information about the epitopes had been collected, the TrV 
structure was analysed and the best mutation sites were selected (Table 8 and Figure 
22). Then the replacement of the amino acids from the tertiary structure of the TrV by 
the amino acids of the epitopes was made, based on the solvent exposure values (in 
Attachments F-H) and trying to mimic their native form. Both these parameters were 
the base of the design process: the regions selected in TrV had similar values to the 
original regions on GP63. 
 
Table 8: Regions of mutation on TrV by epitope. 
Epitope 
Region of mutation 
on TrV 
Images 
Epi-1 94-109 of VP1 23 
Epi-2 159-174 of VP2 24 
Epi-3 237-249 of VP3 25 
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Figure 22: Representation of the TrV protomer with the mutation regions highlighted: Red - Epi-1; 




Figure 23: Detailed view of the most exposed amino acids of Epi-1 inserted in TrV. Images obtained 
using UCSF Chimera (Pettersen et al. 2004). 
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Figure 24: Detailed view of the most exposed amino acids of Epi-2 inserted in TrV. Images obtained 
using UCSF Chimera (Pettersen et al. 2004). 
 
Figure 25: Detailed view of the most exposed amino acids of Epi-3 inserted in TrV. Images obtained 
using UCSF Chimera (Pettersen et al. 2004). 
 
A point to mention about the insertion point for Epi-3, is that when the protomer 
assembled to form the capsid, the Epi-3s of three protomers were close to each other, as 
shown in Figure 26 and Figure 28. 
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Figure 26: Detailed view of the Epi-3 of three distinct protomers. Images obtained using PyMOL 
(Schrodinger LLC 2010). 
 
Following the mutation, done in Coot, some of the residues had to be rotated so 
they would not form undesirable contacts with neighbouring residues. Afterwards the 
exposition, disulfide bonds and saline bridges were analysed, to see the mutation 
degree. The exposition was analysed by ASA-View, the disulfide bonds by a script 
found in pymolwiki and the saline bridge by VMD. 
In Epi-1, a saline bridge was found, between residues of the epitope ARG 100 – 
GLU 105, that was not previously present, i.e. in the native structures of GP63 or TrV, 
however the consequence of this can not be speculated without further molecular 
dynamics studies.  
Another difference found after mutation was on the Epi-3. As said before, GP63 
has cysteines, in contrast with TrV, and the Epi-3 had a disulfide bond (Figure 27) that 
when inserted in TrV was lost. Two possible solutions were conjectured: or add a 
cystein to the TrV in order to favour the formation of a disulfide bond, or to eliminate 
the cystein from Epi-3. Nonetheless, because this issue requires more studies, was 
decided to maintain the cystein in the Epi-3 without doing any additional change into 
TrV structure. 
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Figure 27: Detailed view of the disulfide bond in GP63, before mutation. Images obtained using PyMOL 
(Schrodinger LLC 2010). 
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 Finally, when all necessary changes were done the result was a VLP based on 
TrV with 3 epitopes from GP63 of Leishmania major. In Figure 28, the final result of 
the design is shown. It is distinguishable the pentamere (light grey) and all the epitopes: 
Epi-1 in red, Epi-2 in green and Epi-3 in orange. Besides, it is possible to have a general 
view of the overlap between the Epi-3 of different protomers. 
 
 
Figure 28: Final result: Capsid of TrV with the three epitopes inserted: Epi-1 - Red; Epi-2 - Green; Epi-
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5. Conclusions and Future Perspectives  
 
The work developed had the main objective of elaborating different models of 
DNA immunization as a strategy for vaccination against African Trypanosomiasis. The 
results obtained were analyzed and discussed taking into account previous works in this 
field, even though, the DNA vaccination against this disease has been poorly studied.  
1- Cloning the genes MSP and PLC of the bloodstream forms of Trypanosoma 
brucei brucei in pVAX1 and pET28a: All of the plasmids were successfully cloned and 
characterized by restriction analysis, however, when it comes to automated sequencing, 
the PLCpET28a was the only one that was impossible to obtain a sequence. 
2- Use the plasmids MSPpET28a and PLCpET28a to express the recombinant 
protein of MSP and PLC in Escherichia coli: Although several conditions were used to 
achieve this goal, none of the recombinant proteins were expressed, possibly due to the 
fact that the proteins in study are membrane proteins with partially hydrophobic 
surfaces, flexibility and lack of stability. In order to overcome this issue and to 
accomplish the expression of the recombinant proteins, it would be crucial to amplify 
the extracellular portion of the genes. 
3- In silico analysis and design the epitopes as candidates to the VLPs: With the 
analysis in silico, it was possible to collect some additional information about the 
proteins being used, like, for example, both proteins are extracellular and the zinc motif 
domain of the MSP was identified. Additionally, the analysis facilitated the search for a 
homologous of the MSP, in order to make the design of the VLPs, since it was not 
possible to use the original proteins, once that they have no tertiary structure or 
antigenic epitopes described. Regarding this model of immunization, the next step 
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4- Use the plasmids MSPpVAX1 and PLCpVAX1 as model to the development 
of DNA vaccines against Trypanosoma brucei, determine anti-Trypanosoma brucei 
antibodies and identify native proteins with serum from immunized mice by DNA 
vaccine, and challenge the mice with a lethal dose of Trypanosoma brucei brucei: The 
plasmids MSPpVAX1 and PLCpVAX1 were used as models of DNA vaccines, with 4 
different compositions, the immunization protocol was followed, and the antibodies 
anti-Trypanosoma brucei brucei were measured and, although the titres were relatively 
low, they were more evident in groups immunized with PLCpVAX1, 
MSPpVAX1+PLCpVAX1 and MSPpVAX1+PLCpVAX1+nanoxylan, the last one 
presented higher titres, which probably means that the nanoxylan works as an adjuvant. 
However, the proteins identified did not have the expected molecular weights of MSP 
and PLC, and the intensity of the bands suggests low levels of protein expression in the 
mice. Although none of the immunized mice was able to control the infection, they 
were able to survive longer to it. In the future, some adjustments to the present 
prototypes are needed, such as: increase the number of animals used, increase the 
number of plasmids injections, optimize the immunization times, increase the amount of 
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Solution P1 - Alkaline lysis 
 -10 mM EDTA 
 - 50 mM Glucose 
 - 25 mM Tris-HCl pH 8.0 
 
Solution P2 - Alkaline lysis 
 - 200 nM NaOH 
 - 1% SDS 
 
Solution P3 - Alkaline lysis 
 - 3M Potassium Acetate pH 5.0 
 
Solution 1 - HIC 
 - 10 mM Tris-HCL pH 8.0 
 - Water MQ sterile  
 
Solution 2 - HIC 
 - 1.5 M Ammonium Sulphate; 
Prepared in Solution 1 
TBS 10X (Triphosphate Buffer Saline) 
- 50 mM Tris-HCl pH 8.0 
- 150 mM NaCl 
- Deionized Water q.s. 1.0 L; pH 7.5 
PBS 10X (Phosphate Buffer Saline) 
 - 27 mM de KCl  
 - 1,37 M de NaCl  
 - 17,6 mM de KH2PO4  
 - 101,4 mM de Na2HPO4  
 - Deionized Water q.s. 1,0 L; pH 7,4. 
 
Bicarbonate Buffer 0.1 M pH 8.5 
 - 0,1 M de NaHCO3  
 
Citrate Buffer pH 5.0 
 - 24,3 mL Citric Acid 0.1 M  
 - 25,7 mL Sodium Phosphate 0.1 M  
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Attachment F - Exposition values of Epi-1. 
Residue Exposition on GP63 
Exposition on mutated 
TrV 
Y 0.140370 0.608270 
D 0.200825 0.422425 
Q 0.022396 0.778261 
L 0.311277 0.032766 
V 0.123614 0.006506 
T 0.043254 0.086508 
R 0.061124 0.117882 
V 0.130120 0.013012 
V 0.000000 0.104096 
T 0.000000 0.064881 
H 0.098946 0.005497 
E 0.183168 0.017172 
M 0.004997 0.024985 
A 0.000000 0.000000 
H 0.115437 0.032982 
A 0.000000 0.063518 
 
 
Attachment G - Exposition values of Epi-2. 
Residue Exposition on GP63 
Exposition on mutated 
TrV 
T 0.043254 0.036045 
R 0.061124 0.113516 
V 0.130120 0.097590 
V 0.000000 0.611564 
T 0.000000 0.014418 
H 0.098946 0.071461 
E 0.183168 0.400680 
M 0.004997 0.434739 
A 0.000000 0.226850 
H 0.115437 0.082455 
A 0.000000 0.617032 
L 0.005461 0.305816 
G 0.000000 0.216002 
F 0.004982 0.000000 
S 0.162108 0.179172 




  7. Attachments 
 
  87  
Attachment H - Exposition values of Epi-3. 
Residue Exposition on GP63 
Exposition on mutated 
TrV 
I * 0.691840 
I * 0.810750 
K * 0.549293 
S 0.767880 0.017064 
Y 0.262024 0.463221 
A 0.117962 0.217776 
G 0.000000 0.025412 
L 0.000000 0.043688 
C * 0.104085 
A 0.000000 0.009074 
N 0.116110 0.006830 
V 0.006506 0.000000 
Q 0.279950 0.027995 

















  7. Attachments 
 
  88  
Attachment I – Ribbon model of the TrV pentamer with the mutation regions 
highlighted: Red – Epi-1; Green – Epi-2; Orange – Epi-3. Images obtained using 
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Attachment J - Surface model of the TrV pentamer with the mutation regions 
highlighted: Red – Epi-1; Green – Epi-2; Orange – Epi-3. Images obtained using 
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Attachment K – Ribbon model of the capsid of TrV with the three epitopes inserted: 
Red – Epi-1; Green – Epi-2; Orange – Epi-3. Images obtained using PyMOL 
(Schrodinger LLC 2010). 
 
 
